Alto Neuroscience (ANRO) Non Operating Income (2023 - 2026)
Alto Neuroscience (ANRO) reported Non Operating Income of $901000.0 for Q1 2026, up 77.71% on a YoY basis from $507000.0 in Q1 2025, and up 3.21% sequentially from $873000.0 in Q4 2025.
Alto Neuroscience (ANRO) Non Operating Income (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Non Operating Income data on file, last reported at $901000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 77.71% year-over-year to $901000.0; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (down 47.6% YoY), and the FY2025 full-year result was $3.1 million, down 56.46% from the prior year.
- Non Operating Income rose to $901000.0 in Q1 2026, from $873000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $2.3 million in Q2 2024 to a low of -$83000.0 in Q1 2023.
- A 4-year average of $977692.3 and a median of $873000.0 in 2025 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income soared 1267.47% in 2024 and tumbled 63.39% in 2025, its largest moves.
- Tracing ANRO's Non Operating Income over 4 years: stood at $548000.0 in 2023, then jumped by 227.74% to $1.8 million in 2024, then sank by 51.39% to $873000.0 in 2025, then rose by 3.21% to $901000.0 in 2026.
- Business Quant data shows ANRO's Non Operating Income at $901000.0 in Q1 2026, $873000.0 in Q4 2025, and $770000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Alto Neuroscience | 869.36 Mn | 869.36 Mn | - | 901,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 901,000.00 |
| Dec 31, 2025 | 873,000.00 |
| Sep 30, 2025 | 770,000.00 |
| Jun 30, 2025 | 976,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.31 Mn |
| Mar 31, 2024 | 969,000.00 |
| Dec 31, 2023 | 548,000.00 |
| Sep 30, 2023 | 577,000.00 |
| Jun 30, 2023 | 462,000.00 |
| Mar 31, 2023 | -83,000.00 |